SCHEMBL4124525

SCHEMBL4124525

CCc1ccc(NC(=O)Nc2ccc(C)cc2C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.55
NTRK2 Q16620 1/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 2/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
ALDH1A1 P00352 2/20 0.51
HTT P42858 1/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
CXCR2 P25025 1/20 0.51
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106843 0.88 RAB9A (0.56) NTRK1NTRK2MEN1KMT2ARAB9A
SCHEMBL4548287 0.88 MEN1 (0.61) MEN1KMT2ARAB9ASMN1; SMN2TP53
SCHEMBL4124716 0.86 RAB9A (0.56) MEN1KMT2ARAB9ASMN1; SMN2TP53
SCHEMBL4121977 0.86 IDH1 (0.61) MEN1KMT2ARAB9ASMN1; SMN2CA12
SCHEMBL4112512 0.84 RAB9A (0.69) MEN1KMT2ARAB9ASMN1; SMN2TP53
SCHEMBL4106038 0.83 RAB9A (0.70) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL13853016 0.83 HTT (0.58) MEN1KMT2ARAB9ASMN1; SMN2CA12
SCHEMBL11350134 0.82 MEN1 (0.71) MEN1KMT2ARAB9ASMN1; SMN2L3MBTL1
SCHEMBL14561170 0.82 RAB9A (0.67) MEN1KMT2ARAB9ASMN1; SMN2TP53
SCHEMBL4548043 0.82 SMN1; SMN2 (0.74) MEN1KMT2ARAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 NTRK1 949/4885NTRK2 684/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.